Endomorphin
| Category | Compounds |
|---|---|
| Also known as | Endomorphin-1, Endomorphin-2, EM-1, EM-2 |
| Last updated | 2026-04-14 |
| Reading time | 6 min read |
| Tags | opioidendogenousmu-receptorpainanalgesianeuropeptide |
Overview
The endomorphins are a pair of tetrapeptides — endomorphin-1 (Tyr-Pro-Trp-Phe-NH₂) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH₂) — identified in 1997 by Zadina and colleagues. They are remarkable for possessing the highest affinity and selectivity for the mu-opioid receptor (MOR) of any known endogenous peptide, exceeding beta-endorphin, the enkephalins, and dynorphin by substantial margins in selectivity profiles.
Prior to the discovery of endomorphins, a paradox existed in opioid pharmacology: the mu-opioid receptor was the most clinically important opioid receptor (mediating analgesia, euphoria, respiratory depression, and dependence), yet no endogenous ligand with high selectivity for it had been identified. Beta-endorphin, while having good MOR affinity, also binds delta and kappa receptors. Enkephalins prefer delta receptors. Dynorphins prefer kappa receptors. The endomorphins filled this gap, providing the first endogenous ligands with genuine MOR preference.
However, the endomorphins remain scientifically unusual in one important respect: their biosynthetic origin is unknown. Unlike all other endogenous opioid peptides, no precursor protein gene has been identified. They are not derived from POMC, proenkephalin, or prodynorphin. This has led to ongoing debate about whether they are truly gene-encoded peptides synthesized by a novel mechanism, enzyme-assembled peptides, or perhaps dietary or microbial in origin. Despite this uncertainty, their presence in the brain and spinal cord has been confirmed by multiple laboratories using mass spectrometry and immunohistochemistry.
Amino Acid Sequences
Endomorphin-1 (EM-1): Tyr-Pro-Trp-Phe-NH₂
- Molecular weight: 610.7 g/mol
- CAS Number: 178925-54-7
- Distribution: Predominantly brain (cortex, thalamus, hypothalamus, amygdala)
Endomorphin-2 (EM-2): Tyr-Pro-Phe-Phe-NH₂
- Molecular weight: 571.7 g/mol
- CAS Number: 178925-55-8
- Distribution: Predominantly spinal cord and lower brainstem
Structural features:
- C-terminal amidation — essential for MOR binding
- N-terminal tyrosine — conserved across opioid peptides; provides the pharmacophore for opioid receptor interaction
- Proline at position 2 — constrains backbone conformation, favoring a turn structure that fits the MOR binding pocket
- No Gly-Gly-Phe motif — unlike enkephalins and endorphins, endomorphins lack the canonical opioid peptide sequence
- Unusually small for a neuropeptide — only 4 amino acids
Mechanism of Action
Mu-Opioid Receptor Selectivity
Endomorphins display extraordinary MOR selectivity:
| Peptide | MOR Affinity (Ki) | DOR Affinity | KOR Affinity | MOR Selectivity Ratio |
|---|---|---|---|---|
| EM-1 | 0.36 nM | 1,530 nM | >10,000 nM | >4,000x over DOR |
| EM-2 | 0.69 nM | 5,400 nM | >10,000 nM | >7,000x over DOR |
| Beta-endorphin | 1.0 nM | 1.5 nM | 48 nM | ~1.5x over DOR |
| Morphine | 1.8 nM | 90 nM | 317 nM | ~50x over DOR |
This selectivity profile surpasses even morphine and other synthetic opioids, which typically show 50-100x MOR preference.
Signaling
MOR activation by endomorphins triggers:
- Gi/Go coupling — inhibits adenylyl cyclase, reducing cAMP levels
- GIRK channel activation — opens inwardly rectifying potassium channels, hyperpolarizing neurons
- Calcium channel inhibition — reduces presynaptic neurotransmitter release
- Beta-arrestin recruitment — mediates receptor internalization and potentially biased signaling
Endomorphin-1 may exhibit biased agonism at MOR, favoring G-protein signaling over beta-arrestin recruitment compared to DAMGO and other reference MOR agonists. This has generated interest in whether endomorphin-based analogs could provide analgesia with reduced side effects.
Anatomical Distribution
- EM-1: Concentrated in cortex, thalamus, hypothalamus, amygdala, and periaqueductal gray — regions associated with supraspinal pain modulation, emotional processing, and reward
- EM-2: Concentrated in the spinal dorsal horn and lower brainstem — consistent with a role in spinal analgesia and peripheral nociceptive processing
- This complementary distribution suggests EM-1 and EM-2 serve distinct physiological roles at different levels of the pain processing hierarchy
Research Summary
| Area of Study | Key Finding | Notable Reference |
|---|---|---|
| Discovery | Two tetrapeptides with unprecedented mu-opioid receptor selectivity isolated from bovine brain | Zadina et al., Nature, 1997 |
| Analgesia | Intrathecal and ICV endomorphin produces potent analgesia in rodent pain models | Horvath, Pharmacology & Therapeutics, 2000 |
| Biased agonism | EM-1 may favor G-protein signaling over beta-arrestin at MOR; implications for side effect profile | Rivero et al., British Journal of Pharmacology, 2012 |
| Tolerance | Repeated endomorphin administration produces less tolerance development than morphine in some paradigms | Przewlocka et al., Annals of the New York Academy of Sciences, 1999 |
| Biosynthetic mystery | No precursor gene identified; possible enzyme-catalyzed synthesis via DPE (dipeptidyl peptidase) | Ronai et al., Regulatory Peptides, 2009 |
| Immune modulation | Endomorphins modulate immune cell function via MOR on lymphocytes and macrophages | Jessop et al., Brain, Behavior, and Immunity, 2002 |
| Anti-inflammatory | EM-1 and EM-2 show anti-inflammatory effects in peripheral tissues independent of central analgesia | Khalil et al., Peptides, 2006 |
| Cardiovascular | Endomorphins produce cardiovascular effects (hypotension, bradycardia) consistent with MOR activation in brainstem | Champion et al., Peptides, 2002 |
Pharmacokinetics
- Half-life: Very short — approximately 1-3 minutes in plasma due to rapid enzymatic degradation
- Degradation: Primarily by dipeptidyl peptidase IV (DPPIV, cleaves Tyr-Pro bond) and aminopeptidases
- Route (research): Intrathecal, intracerebroventricular, or with structural modifications for systemic delivery
- BBB penetration: Limited; endomorphins do not readily cross the blood-brain barrier after peripheral administration
- Stability challenge: The extremely short half-life has been the primary obstacle to therapeutic development; numerous analogs with improved stability have been synthesized
Common Discussion Topics
-
The missing gene problem — No precursor gene has been identified for endomorphins despite extensive genomic searches. Hypotheses include synthesis by a non-ribosomal peptide synthetase, assembly by dipeptidyl enzymes, or derivation from an unidentified precursor. This remains one of the most intriguing open questions in neuropeptide biology.
-
Biased agonism and safer opioids — Endomorphin's potential G-protein bias at MOR has attracted interest in the context of designing opioid analgesics that produce pain relief with less respiratory depression, tolerance, and addiction — a major goal of pain pharmacology research.
-
Comparison with exogenous mu agonists — Dermorphin, an exogenous peptide from frog skin, is another highly potent MOR agonist. Comparing its selectivity to endomorphins illuminates the structural determinants of MOR preference.
-
The endogenous opioid hierarchy — With endomorphins for MOR, enkephalins for DOR, and dynorphin for KOR, the endogenous opioid system has a complete set of receptor-selective ligands, each with distinct physiological roles.
-
Spinal vs. supraspinal distribution — The differential distribution of EM-1 (brain) and EM-2 (spinal cord) suggests evolution selected for compartmentalized mu-opioid signaling at different levels of the neuraxis.
Related Compounds
- Beta-Endorphin — 31-amino acid endogenous opioid with broader receptor profile (MOR + DOR)
- Enkephalins — pentapeptide endogenous opioids preferring delta receptors
- Dynorphin — endogenous opioid preferring kappa receptors
- Dermorphin — exogenous frog skin peptide with high MOR potency
- Ziconotide — non-opioid intrathecal analgesic from cone snail venom
Sourcing research-grade compounds
Obtaining high-purity, research-grade Endomorphin requires verified and trusted suppliers with third-party COA testing and transparent sourcing practices.
White Market Peptides — Verified Supplier →Join the discussion
See how the community is discussing Endomorphin. Share your experience, ask questions, and explore protocols on PepAtlas.
Related entries
- Beta-Endorphin— A 31-amino-acid endogenous opioid peptide derived from proopiomelanocortin (POMC), acting primarily at mu-opioid receptors to modulate pain perception, reward, and stress responses, and famously associated with the 'runner's high' phenomenon.
- Dermorphin— A seven-amino-acid opioid peptide originally isolated from the skin of South American tree frogs, approximately 30-40 times more potent than morphine at the mu-opioid receptor.
- Dynorphin— A family of endogenous opioid peptides derived from the prodynorphin precursor, dynorphins are the primary endogenous ligands of the kappa-opioid receptor and are implicated in pain modulation, stress responses, dysphoria, addiction neurobiology, and neuroendocrine regulation.
- Enkephalins— The first endogenous opioid peptides to be discovered, met-enkephalin and leu-enkephalin are pentapeptides that preferentially activate delta-opioid receptors to modulate pain perception, reward, mood, and immune function, serving as the body's intrinsic analgesic signaling molecules.
- Ziconotide— A synthetic 25-amino-acid peptide derived from the venom of the marine cone snail Conus magus, ziconotide is a highly selective N-type voltage-gated calcium channel blocker administered intrathecally for severe chronic pain refractory to other analgesics.